QB3 Seminar: George Scangos, Vir Biotechnology

Vir Biotechnology is at the forefront of the battle against infectious disease, including SARS-CoV-2. Join us on May 6 to hear about the latest developments at Vir from George Scangos, PhD, the company’s President and CEO, in conversation with QB3 Executive Director Reg Kelly, PhD, OBE.

Vir is developing platform technologies to stimulate and enhance the immune system. Dr. Scangos previously led Biogen, Exelixis, and Bayer Biotechnology, and has served on the boards of several publicly traded companies. We look forward to his insights and perspective.

Where & When

Zoom webinar
1:00 to 2:00 PM, Wednesday, May 6, 2020

This event was recorded. View it on YouTube

About the Speaker

George Scangos, Ph.D., has served as Vir’s President and Chief Executive Officer and as a member of the board of directors since January 2017. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc., a publicly traded biopharmaceutical company focused on the treatment of serious diseases. From October 1996 to July 2010, Dr. Scangos served as President and Chief Executive Officer at Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer Biotechnology’s biological products. Before joining Bayer Biotechnology in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University. Dr. Scangos has served as a member of the board of directors of various publicly traded companies, including: Exelixis, Inc., since 1996; Agilent Technologies, Inc., a life sciences, diagnostics and applied chemical analysis company, since 2014; and Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2010. Dr. Scangos served as Chair of PhRMA in 2016, and as the Chair of the California Healthcare Institute in 2010. He was a member of the board of directors of the Global Alliance for TB Drug Development from 2006 until 2010. Dr. Scangos currently serves on the Board of Trustees of Cornell University and the Board of Overseers of the University of California, San Francisco. Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.

QB3 Seminar: Sean George, Invitae. "Acquisition as Growth Strategy in the Diagnostics Space"

Many founders hope to grow their startup to the point that it is acquired by a larger company. But startups can grow by acquiring other companies and technologies themselves. How does acquisition give you a stronger position in the market? Join us on Thursday, April 16 to learn from Sean George, CEO of Invitae, a genetic information company which has made 10 acquisitions since 2017.

About the Speaker

Sean is chief executive officer of Invitae, whose mission is to bring genetic information into mainstream medicine. Prior to his CEO position, he served as Invitae’s president and chief operating officer. Sean was a co-founder and CEO of Locus Development, an early stage genetic analysis startup that later merged with Invitae. Prior to co-founding Locus, he served as COO at Navigenics, an early leader in personalized medicine. Previously, he has also served as SVP of Marketing and SVP, Life Science Business at Affymetrix as well as VP, Labeling and Detection Business at Invitrogen. In the past, he has also worked at McKinsey & Co. and Molecular Probes. Dr. George holds a B.S. in Molecular Genetics from UCLA, an M.S. in Molecular Biology from UC Santa Barbara, and a Ph.D. in Molecular Genetics from UC Santa Cruz.

*CANCELED* Rosenman D-Series: Aaron Sandoski, Norwich Ventures. "What Is Success in Healthtech Convergence?"

Unfortunately, due to COVID-19 concerns, Norwich Ventures has instated a company travel ban. Attendees with paid tickets will be refunded. Aaron is unable to travel to San Francisco for this talk. He expects to be able to make it in the fall, and we look forward to seeing you then.

Startup founders whose technologies embody the convergence of AI, data, or telehealth with traditional engineering must develop wide-ranging business models. It is no longer enough to focus on a product by itself; founders must take a systems approach and consider all stakeholders that interact with the data or technology. Aaron Sandoski, co-founder & managing director of Norwich Ventures, will explain how his investment firm assesses early-stage companies with convergent technologies.

Where & When

Room N-114, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Tuesday, March 10, 2020, 5:30 to 6:30 PM

About the Speaker

Aaron Sandoski is Co-Founder & Managing Director of Norwich Ventures, a specialized venture capital firm focused on early-stage MedTech.  Aaron’s current investments include Affera, Arterys, Lexington Medical, Pelvalon, Podimetrics, ReThink Medical and Vaxess Technologies.  Previous investments include Rhythmia Medical (acquired by Boston Scientific) and Intelligent Bio-systems (acquired by Qiagen).  Prior to founding Norwich Ventures, Aaron worked for DEKA R&D, the engineering think tank of Dean Kamen.  He has also worked in start-up operations where he helped launch a subsidiary of Express Scripts and helped launch a venture-backed payments company. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system.  Aaron is co-author of How the Wise Decide (Crown Business), a book on best practices in making tough decisions, which has been translated into 11 foreign languages.  Aaron earned an MBA from Harvard Business School and graduated summa cum laude from Dartmouth College with a double A.B. in Chemistry and Economics.

Rosenman D-Series: Sam Williams, Brown Rudnick. "How to Prepare to Sell Your Life Science or Medtech Company"

To ensure a successful sale of your startup you need to start planning early. Several issues are key. Among them: how to maximize value; how to manage stakeholders; and how to close the deal, which is everything once you decide to sell. To learn how to do it right—as well as hard-learned lessons about what happens if you don't—join us on Thursday, February 20 to hear from Sam Williams, a partner in corporate law at the firm Brown Rudnick.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:30 to 6:30 PM, Thursday, February 20, 2020

About the Speaker

Sam Williams concentrates his practice on corporate finance, mergers and acquisitions, venture capital, licensing and strategic partnerships and international law. He counsels publicly and privately held corporations in a variety of industries including businesses in the information technology, semiconductor, communications and other high technology sectors.

In addition to his transactional experience, Sam has considerable experience guiding clients in formulating their intellectual property, licensing and distribution arrangements and in establishing domestic and multinational strategic partnerships. He advises clients in complying with securities laws in proxy solicitations, the ongoing reporting requirements of public companies, antitakeover techniques and a broad range of other matters affecting companies and their officers and directors.

As part of Brown Rudnick’s Family Office team, Sam is also part of collaborative, cross-disciplinary initiatives assisting clients in this area.

Sam is consistently recognized in Chambers USA: America’s Leading Lawyers for Business as well as being recognized by his peers for inclusion in The Best Lawyers in America© in the field of Corporate Law.

QB3 Seminar: Anna Christensen, CEO & Co-Founder, Magnetic Insight. "Disrupting the Magnetic Imaging Market"

Magnetic Insight is an Alameda-based, early stage company that has commercialized a disruptive new medical imaging platform complementing CT, MRI and PET workflows with magnetic particle imaging, a precise and sensitive new imaging modality for vascular imaging, inflammation staging and cell therapy monitoring. Last July the company moved into a 22,000 square foot facility where they have set up a state of the art operation to develop and manufacture a line of products that now ship worldwide. Join us on Tuesday, February 11, to hear from Anna Christensen, who will relate the lessons she has learned as the company’s co-founder and CEO.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Tuesday, February 11

This is a brown bag event.

About the Speaker

Dr. Anna Christensen is the CEO and co-founder of Magnetic Insight. She has spent the last 16 years commercializing platform technologies in imaging and diagnostics. Most recently, she led the in vivo imaging business for PerkinElmer Inc and Caliper Life Sciences as the global business leader. Prior to Caliper Life Sciences, she held senior management positions at DiscoverX and Molecular Devices. In addition to her commercial experience, she holds advanced degrees in cell biology and neurobiology from UC San Diego and Copenhagen University.

Expert Consult: Joe Snyder, Kilpatrick Townsend. IP & Confidentiality

Would you like legal advice on how to handle IP & confidentiality in your interactions with potential partners and investors? Apply to join our upcoming session with Joe Snyder, PhD, Partner at the law firm Kilpatrick Townsend.

Our office hours are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.

If you choose a timeslot, we will require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.

If you find that you are unable to attend, you may request a refund up to 5 days in advance. (This will give us time to offer the slot to the first person on the waitlist.) We regret that we cannot honor requests made at a later time.

Where & When

Suite 214, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Thursday, February 20, 2020

Applications are now closed.

About Joe Snyder

Joseph Snyder is the Managing Partner of Kilpatrick Townsend's Walnut Creek office. He focuses his practice on patent prosecution and counseling, emphasizing patent drafting, patent procurement, client counseling and opinion writing, primarily in the chemical arts, biotechnology, life sciences and clean technology. He counsels clients on planning and portfolio analysis for patent protection, including strategic review of technologies' commercial potential, enforcement of patent rights and defense of infringement allegations. Dr. Snyder represents U.S. and foreign companies, such as pharmaceutical companies, diagnostic laboratories, universities and start-ups in all areas of intellectual property counseling and protection.

Meet One-on-One with Bio-Rad at QB3

Bio-Rad, a leader in products for life science research and clinical diagnostics, and based in the Bay Area community of Hercules, continually seeks to increase its portfolio of innovative technologies.
 
Bio-Rad is interested in meeting startups in the QB3 ecosystem. To facilitate mutually beneficial partnerships, we are coordinating a partnering session Wednesday, December 11 at UCSF Mission Bay.
 
Space is limited. If you see an opportunity in partnering with Bio-Rad, please apply thru Wednesday, November 13.

Areas of Interest

Before you apply, please note that Bio-Rad is interested in technologies whose applications fall in the following areas:

In life science research:

• Single cell biology (genomics and proteomics)

• Protein characterization

• Digital genomics and translational research

• New generation sequencing technology

In clinical diagnostics:

• Microbiome

• Point of care technologies

• Microbiology, including antibiotic susceptibility

• New biomarkers

• Food safety

• Wearables, mHealth

Download the full scope document

QB3/UC Hastings FTO Application Spring 2020

Patenting your invention is just one step in being able to commercialize a technology. Just being granted a patent does not guarantee that you will ultimately be successful. You need to make sure that you are not infringing on existing patents that could limit your ability to apply your technology. Ensuring that you have "Freedom to Operate" (FTO) can take many hours of a patent attorney's time.

To provide FTO analysis to selected startups at no charge, QB3 has partnered with UC Hastings. For companies accepted to the program, a team of law students with technical backgrounds will perform an FTO analysis under the supervision of an experienced attorney. The company has to interact with the students weekly to ensure progress of the project. This is a selective program. Approximately four applications will be chosen based on a match with the law students' technical background and interests. Strong preference will be given to incorporated companies with issued patents.

Applicants will learn of their status by the end of December.

To apply via our platform on SurveyMonkey Apply, click the button below. If you have not previously used SurveyMonkey Apply, there is a quick registration stage before you can fill out the form.

The deadline to apply is 5 PM on Friday, December 6.

---

Also of interest: The Startup Legal Garage at UC Hastings Law School has a Corporate Services Program that provides assistance with equity distribution, terms of service, vendor, customer, and employment contracts, basic funding work, and more. Startups in the corporate program pay no legal fees or equity. Our attorney partners oversee the student teams to make sure the work is done right, and our startups can spend their funding building their product instead of on legal bills. Eligibility: <$1M in funding. To avoid conflicts of interest, it is highly desirable that your company not already have a current active relationship with an attorney.
Apply thru Sunday, december 15

Rosenman D-Series: Tak Cheung, NEA. “VC Healthtech Investing at NEA”

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:30 to 6:30 PM, Thursday, December 5, 2019

About the Speaker

Tak joined NEA in 2018 as a Principal on the healthcare team. He focuses on medical device investments.

Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).

Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.

QB3 Seminar: "Machine Learning in Science: Lessons Learned at Riffyn," Tim Gardner, CEO & Founder, Riffyn.

Tim Gardner founded and leads Riffyn, a global provider of Software-as-a-Service for scientific process design and data analytics. The Oakland-based startup recently closed a $15 million Series B round and announced a collaboration with BASF. At this talk, Tim will relate his motivation for starting Riffyn and discuss challenges he and his team have faced and overcome.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, December 5, 2019

This is a brown bag event.

About the Speaker

Timothy Gardner is the Founder and the CEO of Riffyn. He was previously Vice President of Research & Development at Amyris, where he led the engineering of yeast strain and processes technology for large-scale bio-manufacturing of renewable chemicals. Earlier, he was an Assistant Professor of Biomedical Engineering at Boston University, the Founder of Cellicon Biotechnologies, and a Programmer at ALK Associates. Tim has been recognized for his pioneering work in Synthetic Biology by Scientific American, the New Scientist, Nature, Technology Review, and the New York Times. He also served as an advisor to the European Union Scientific Committees and the Boston University Engineering Alumni Advisory Board. He holds BS in Mechanical Engineering from Princeton University and a PhD in Biomedical Engineering from Boston University.

About Riffyn

Riffyn provides cloud-based process design and data analytics to R&D organizations in biotech, pharmaceutical, food and chemical industries. Riffyn’s cloud-based Scientific Development Environment (Riffyn SDE) gives customers the power to achieve repeatable outcomes, faster discoveries, and right-first-time technology scale-up. Riffyn serves enterprise R&D customers across the US, Asia, Europe and South America, and has headquartered in Oakland, CA. For more information, visit: www.riffyn.com.

QB3 Seminar: Jennifer Kenny. "How to Be an Entrepreneur and a Leader"

As an entrepreneur you are not just building a company. You are also leading people and creating partnerships. You can improve your chances of leadership success by applying "Human Innovation," a process that integrates design thinking, systems thinking, and human cognition and language. Human Innovation enables entrepreneurs to leverage the innovative capacity of their teams and the ecosystem so they can thrive. Join us November 14th to learn more from Jennifer Kenny, a mentor and trainer who specializes in advising CEOs on leading innovation in complex technical environments.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, November 14, 2019

This is a brown bag event.

About the Speaker

Jennifer Kenny speaks, mentors, trains and facilitates on Human Innovation, with a specific focus on two of the big levers of innovation: technology and gender diversity. Her work is founded on Systems Thinking and Language Action Design/Human Centered Design.

Jennifer has held senior consulting positions with Accenture, Booz Allen and Gartner, senior executive roles with Wells Fargo and Cisco, and was CIO, SRI International (formerly Stanford Research Institute) where she designed and led the enterprise’s IT transformation program.

Jennifer was most recently honored at the 2019 Silicon Valley Global Awards. She was awarded the internationally acclaimed IDG DEMO Entrepreneurship Award and won the Intel/University of California Business Plan Award. Jennifer is on the Board of Directors of Global Women's’ Leadership Network and is a Fellow of the Irish Computer Society. Jennifer holds a M.Sc. (Hons.), in Engineering Geology, Imperial College, University of London, a B.Sc.(Hons), in Geology and Chemistry from University College, Dublin. She currently lives in San Francisco.

QB3 Seminar: Tito Serafini, Atreca. "Lessons Learned at Atreca from Founding Through IPO"

Redwood City-based Atreca ("BCEL" on Nasdaq) is developing novel therapeutics based on a deep understanding of the human immune response. In June, Atreca's IPO raised $125 million. Tito Serafini led Atreca as CEO from inception through 2018. Join us on October 31 to get Tito's insights and reflections on the company's founding and growth.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, October 31, 2019

This is a brown bag event.

About the Speaker

Dr. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.

Expert Consult: Joe Snyder, Kilpatrick Townsend. IP & Confidentiality

Would you like legal advice on how to handle IP & confidentiality in your interactions with potential partners and investors? Apply to join our upcoming session with Joe Snyder, PhD, Partner at the law firm Kilpatrick Townsend.

Our office hours are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.

If you choose a timeslot, we will require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.

If you find that you are unable to attend, you may request a refund up to 5 days in advance. (This will give us time to offer the slot to the first person on the waitlist.) We regret that we cannot honor requests made at a later time.

Where & When

Suite 214, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Thursday, October 24, 2019

Apply thru Saturday, October 12.

About Joe Snyder

Joseph Snyder is the Managing Partner of Kilpatrick Townsend's Walnut Creek office. He focuses his practice on patent prosecution and counseling, emphasizing patent drafting, patent procurement, client counseling and opinion writing, primarily in the chemical arts, biotechnology, life sciences and clean technology. He counsels clients on planning and portfolio analysis for patent protection, including strategic review of technologies' commercial potential, enforcement of patent rights and defense of infringement allegations. Dr. Snyder represents U.S. and foreign companies, such as pharmaceutical companies, diagnostic laboratories, universities and start-ups in all areas of intellectual property counseling and protection.

Rosenman D-Series: James Eadie, MD, Santé Ventures. "Investing in Early-Stage Life Science and Healthcare"

This will be an interactive conversation between Dr. Eadie and Christine Winoto, Director and Founder of the UCSF Rosenman Institute. When you register, please let us know what questions you would most like answered.

Where & When

Tuesday, October 22, 2019, 5:30 to 6:30 PM
Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)

About the Speaker

James Eadie, MD, is Partner at Santé Ventures. He joined the firm in 2010. Previously, James served in the Air Force and was the medical director and Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center in San Antonio. He completed two tours in Iraq as a critical care transport team chief and as the emergency department commander. He separated honorably as a Major in 2008. James received his MBA from the University of Texas McCombs School Of Business, his MD from Harvard Medical School, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital.

Rosenman D-Series: Neil Tiwari, dRx Capital. "Investing in Digital Innovation at Novartis"

This will be an interactive conversation between Neil and Christine Winoto, Director and Founder of the UCSF Rosenman Institute. When you register, please let us know what questions you would most like answered.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:30 to 6:30 PM, Thursday, October 10

About the Speaker

Neil is a General Partner at dRx Capital and sits in the Novartis Chief Digital Office. He is a healthcare technology leader with 10+ years of experience developing life sustaining medical devices, diagnostic devices, drug-device combination products and digital health products. His background in product development has allowed him to foster the growth of early stage companies and products in the startup, academic and corporate environments. Prior to dRx, Neil led a digital health product development team at Novartis developing Software as a medical device products (SaMDs) and was a systems engineering manager for drug-device combination products. Prior to Novartis, Neil led a systems engineering team at Baxter Healthcare developing home dialysis devices, cloud based telemedicine solutions, and other medical products. He is an inventor on 6 patents from his work in these areas.

Neil holds a BS cum laude and MS in Biomedical Engineering from Northwestern University where he focused in an electrical engineering/computer science track. He also holds a MBA from the Berkeley Haas School of Business with a focus in venture capital.

QB3 Seminar: David Spellmeyer. "Score! How Your SBIR/STTR Application is Reviewed and Scored"

The SBIR/STTR grant review process can be extremely frustrating and opaque. But if you understand how the reviewers operate, you can improve the chances that your application will succeed. On October 3, David Spellmeyer, an expert SBIR consultant, will reveal the inner workings of an SBIR/STTR Study Section Review Panel. David’s talk will cover panel composition, review assignments, meeting mechanics, critiques, and the scoring process. Join us to learn several ways that you can make your application stand out.

Following David’s talk there will be an extended Q&A session, up to 90 minutes, so we can be sure all questions have been answered.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Thursday, October 3, 12:00 to 1:00 PM

This is a brown bag event.

About the Speaker

Dr. Spellmeyer is a biotechnology executive with 25 years of broad experience in the life sciences industry. He regularly participates in NIH SBIR/STTR Study Sections as both a panel reviewer and as Chair. He currently serves as CSO at Circle Pharma, as an Executive-in-Residence at ShangPharma Innovation, and heads Interlaken Associates where he advises early-stage companies and investors on corporate and technical strategy, product development, and commercialization. He previously served in research leadership roles at both large and small companies. Dr. Spellmeyer received his BS in computer science and chemistry from Purdue University and his PhD in theoretical organic chemistry from UCLA. He completed postdoctoral training in pharmaceutical chemistry at UCSF, where he is an adjunct Associate Professor.

QB3 Seminar: Ira Mellman, Genentech. "Drug Discovery & Development in Cancer Immunology"

Ira Mellman, PhD, is Vice President of Cancer Immunology at Genentech, a world leader in this vital, complex, and exciting field. Join us on Tuesday, September 17 to learn how an understanding of the basic science can inform the quest to discover and develop novel, effective therapies for cancer. Dr. Mellman will also contrast the differing approaches to R&D in industry, academia and startups.

Where & When

Byers Auditorium, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Tuesday, September 17, 2019, noon to 1:00 PM

About the Speaker

Ira Mellman came to Genentech in the Spring of 2007 as Vice President of Research Oncology, after more than 20 years as a faculty member at the Yale University School of Medicine, where he was chair of his department (Cell Biology), a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology and Immunobiology. Dr. Mellman has a BA from Oberlin College & Conservatory and a PhD in Genetics from Yale. He was a Postdoctoral Fellow at the Rockefeller University with Ralph Steinman, who received the Nobel Prize for the discovery of dendritic cells. His laboratory is known not only for advances in fundamental cell biology particularly in the area of membrane traffic (including the discovery of “endosomes”) but also for applying these insights to understanding the cellular basis of the immune response, especially dendritic cell function. He was also the founder of CGI Pharma, which was recently purchased by Gilead. Ira ran all of oncology research at Genentech until the end of 2013 when he decided to concentrate his efforts on the rapidly developing area of cancer immunotherapy and became Vice President of Cancer Immunology. Ira is a member of the National Academy of Sciences, American Academy of Arts & Sciences, the European Molecular Biology Organization, and the former Editor in Chief of the Journal of Cell Biology. He has also served on the editorial boards of Cell, the Journal of Experimental Medicine, EMBO Journal, among others. He also serves on the boards of the Society for the Immunotherapy of Cancer, the American Society for Cell Biology, and the Cancer Research Institute. He remains a frustrated composer and songwriter, and has recorded two CDs in the little-known genre of “bio-rock”.

Expert Consult: Mickey Urdea, PhD. Diagnostics

Would you like expert advice on diagnostics from Mickey Urdea, PhD, Founder & Partner at Halteres Associates?

Our office hours are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.

If you choose a timeslot, we will require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.

If you find that you are unable to attend, you may request a refund up to 5 days in advance. (This will give us time to offer the slot to the first person on the waitlist.) We regret that we cannot honor requests made at a later time.

Where & When

Suite 214, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Tuesday, June 25, 2019

Applications are now closed.

Dr. Mickey Urdea is Founder and Partner for Halteres Associates. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company that has been involved in the prevention of type-2 diabetes (assets acquired by HDL), and was CEO of Quantum Dots Corporation (assets acquired by Life Technologies). Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health (CFH), a non-profit organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring; CFH is developing potential biomarkers for tuberculosis bacterial load with a grant for the Bill & Melinda Gates Foundation. Dr. Urdea is a member of the University of California at San Francisco Leadership Council for Global Health. He serves as a consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology and diagnostics companies. Prior to his current activities, Dr. Urdea founded the Nucleic Acid Diagnostics business at Chiron Corporation, where he pioneered viral load assays for the human hepatitis B, hepatitis C and immunodeficiency viruses; his team introduced the first commercial viral load assays for all three viruses. Dr. Urdea also headed the Oncology Diagnostics business unit at Chiron. He then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He has served as an advisor to the Bill & Melinda Gates Foundation for over ten years. Dr. Urdea is an author on over 200 peer-reviewed scientific publications and has more than 125 issued and pending patents. He received his BS in Biology and Chemistry from Northern Arizona University, his PhD in Biochemistry from Washington State University, and had an NIH postdoctoral fellowship at the University of California at San Francisco.

The Sixth Annual UCSF Rosenman Symposium

Join us Wednesday, June 19, 2019 at UCSF Mission Bay for the Rosenman Symposium, the premier conference for the San Francisco Bay Area's health technology community. Join us to learn from leaders in the health technology industry, meet dynamic startups, and connect with hundreds of players in the Bay Area ecosystem. The event runs 1:30 to 5:30 PM with a reception to follow.

For full information and registration, visit the symposium webpage on the UCSF Rosenman Institute website.

Agenda

Lightning pitches by the 2019 Rosenman Innovators startup cohort featured throughout.

1:30 PM Christine Winoto, Rosenman Institute: Welcome & Introduction

1:40 PM Marie Johnson, AUM Cardiovascular: "Commercializing an Acoustic Device to Detect Coronary Artery Blockage"

2:05 PM Fireside Chat: “A New Approach to Early-Stage Medtech Innovation and Investment: NXT Biomedical”
Andrew ElBardissi, Deerfield Management
Stanton Rowe, NXT Biomedical

-- Break --

3:20 PM John Groetelaars, Hill-Rom: “Advancing Connected Care”

3:45 PM Tippi Mackenzie, UCSF: "Fetal Stem Cell Transplantation"

-- Break --

4:35 PM Panel: “Advances in the Diabetes Space”
Casper de Clercq, Norwest Venture Partners (Moderator)
David Conn, Glooko
Sean Duffy, Omada Health
Harith Rajagopalan, Fractyl
Ruchita Sinha, Sanofi Ventures

-- Reception --

QB3 Seminar: Dennis Schwartz, Repositive. "How to Access Genomic Data for Cancer Therapeutic Discovery"

Cancer drug targets are now largely determined by mutations, rather than tumor tissue. This shift in focus has introduced new challenges for scientists identifying targets. First they must choose the right genomic datasets from disconnected sources; then make aggregate data comparable despite different platforms or analytical pipelines. Human data protection also adds layers of security and legal complexity. In this seminar, we will examine how to overcome these challenges and plan for validating potential targets at the preclinical stage. Download Dennis’s slide deck

Where & When

Room N-114, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Noon to 1:00 PM, Thursday, June 13

About the Speaker

Dennis Schwartz, Bioinformatics Software Developer, Repositive

Dennis is a software developer and bioinformatician with a keen interest in genomic data sharing and open source software. After earning a BSc (Tübingen University) and MSc (TU & LMU Munich) in Bioinformatics he started working for Repositive in 2016. He spent the majority of the past two years working to better understand the needs of Pharma researchers and how they use genomic data in their search for cancer models in drug target validation. His focus is mainly on untangling the often jargon based requirements of biologists, oncologists and pharmacologists into comparable molecular characteristics which can be detected in next generation sequencing data from a variety of sources. Outside of his role at Repositive he is a contributor and maintainer with the BioJS open source project for the visualisation of biological data on the web. Through his open source work he has spoken at and partially organised multiple workshops, talks and a MOOC (as part of a team at TUM) about Javascript and data visualisation.